Microbiome Health Research Institute, operating under the name Openbiome, is located in Woburn, MA. The organization was established in 2013. According to its NTEE Classification (H70) the organization is classified as: Digestive Diseases & Disorders Research, under the broad grouping of Medical Research and related organizations. As of 12/2022, Openbiome employed 27 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Openbiome is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2021, Openbiome generated $6.3m in total revenue. This organization has experienced exceptional growth, as over the past 7 years, it has increased revenue by an average of 12.8% each year . All expenses for the organization totaled $3.2m during the year ending 12/2021. While expenses have increased by 11.3% per year over the past 7 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2021
Describe the Organization's Mission:
Part 3 - Line 1
OPENBIOME IS A PIONEERING NONPROFIT THAT ACCELERATES BOLD DISCOVERIES IN MICROBIOME SCIENCE, ETHICALLY AND EQUITABLY, TO IMPROVE HEALTH FOR ALL.
Describe the Organization's Program Activity:
Part 3 - Line 4a
ALIGNED WITH CURRENT FDA POLICY, OPENBIOME REMAINS COMMITTED TO ENSURING THAT ALL PATIENTS SUFFERING FROM C. DIFFICILE INFECTION CONTINUE TO HAVE SAFE, CONVENIENT, AND AFFORDABLE ACCESS TO FECAL MICROBIOTA TRANSPLANTATION (FMT) THROUGH THEIR PHYSICIAN. IN OUR COLLABORATION WITH THE UNIVERSITY OF MINNESOTA (UMN), UNDER AN ACTIVE INVESTIGATIONAL DRUG APPLICATION (IND), WE CONTINUE TO DISTRIBUTE FMT TO OUR CLINICAL NETWORK AND ARE WORKING WITH FDA TO ENSURE THAT ALL REGULATORY FILINGS ARE KEPT CURRENT AND COMPLIANT WITH THE EXISTING POLICY AND GUIDANCE. WE STRIVE TO MAKE THE PATH TO TREATMENT AS SIMPLE AS POSSIBLE FOR PATIENTS AND THEIR DOCTORS, WHILE BRINGING A LEVEL OF SAFETY AND STANDARDIZATION TO THE PROCESS THAT HAS SET THE STANDARD FOR THIS EMERGING FIELD. OPENBIOME PROVIDES FMT THAT HAS BEEN MANUFACTURED BY UMN AND HAS BEEN RIGOROUSLY SCREENED. THESE READY-TO-USE FECAL MICROBIOTA PREPARATIONS ALLOW PHYSICIANS TO DEVOTE THEIR TIME AND ENERGY TO TREATING PATIENTS, RATHER THAN THE COMPLEXITIES OF MANAGING A STOOL DONOR PROGRAM.
CLINICAL RESEARCH PROGRAM: OPENBIOME SEEKS TO ENABLE TRANSLATIONAL RESEARCH ON THE HUMAN MICROBIOME. TO DO SO, WE PROVIDE A SUITE OF SERVICES TO HELP INVESTIGATORS UNCOVER THE ROLE OF THE GUT MICROBIOME IN HUMAN HEALTH, AND TO DISCOVER HOW ENGINEERING IT CAN DRIVE BETTER HEALTH OUTCOMES. OUR SERVICES INCLUDE THE PROVISION OF CUSTOMIZED FECAL MICROBIOTA PREPARATIONS, STUDY DESIGN AND REGULATORY SUPPORT FOR CLINICAL TRIALS, AND BIOINFORMATICS AND ANALYTICAL SERVICES. OPENBIOME ALSO SPONSORS ITS OWN STUDIES INVESTIGATING CRITICAL MICROBIOME-RELATED HEALTH CONDITIONS.
THE GLOBAL MICROBIOME CONSERVANCY (GMBC) PROGRAM AT OPENBIOME PARTNERS WITH SCIENTISTS AROUND THE WORLD TO CONSERVE, STUDY, AND SHARE UNDERREPRESENTED AND AT-RISK HUMAN MICROBIOME DIVERSITY. THE GMBC HAS ESTABLISHED A NETWORK OF 80+ RESEARCHERS IN OVER THREE DOZEN COUNTRIES AND BUILT A DIVERSE COLLECTION OF SAMPLES AND BACTERIAL ISOLATES TO SPARK SCIENTIFIC DISCOVERY AND ENABLE NEW SOLUTIONS TO MICROBIOME-ASSOCIATED DISEASE.THE GMBC WAS ESTABLISHED TO SOLVE THE URGENT NEED FOR A DEEPER, MORE GLOBALLY REPRESENTATIVE UNDERSTANDING OF THE HUMAN MICROBIOME THAT ADDRESSES THE HEALTH CONCERNS OF ALL. A DEEPER UNDERSTANDING OF THE HUMAN MICROBIOME IS CRITICAL TO SOLVING GLOBAL HEALTH CHALLENGES SUCH AS ANTIMICROBIAL RESISTANCE, MALNUTRITION, DEPRESSION, AS WELL AS AUTOIMMUNE AND METABOLIC DISORDERS THAT ARE LINKED TO THE COMMUNITIES OF BACTERIA THAT LIVE WITHIN US. HOWEVER, OUR CURRENT BODY OF KNOWLEDGE, LARGELY BASED ON U.S. AND EUROPEAN POPULATIONS, IS BIASED AND VASTLY INCOMPLETE. AS INDUSTRIALIZATION DISRUPTS HUMAN MICROBIOME DIVERSITY ON A GLOBAL SCALE, THE WINDOW OF OPPORTUNITY TO STUDY AND APPLY THE FULL POTENTIAL OF THE HUMAN MICROBIOME IS CLOSING. TO RADICALLY EXPAND SCIENTISTS' VIEW OF THE MICROBIOME, THE GMBC PROGRAM HAS BUILT A GLOBALLY REPRESENTATIVE COLLECTION OF HUMAN MICROBIOME SAMPLES, BACTERIAL ISOLATES, AND ASSOCIATED METADATA AS A RESOURCE FOR THE RESEARCH COMMUNITY. WORKING WITH LOCAL SCIENTISTS AROUND THE WORLD, WE COLLECT AND CONSERVE MICROBIOME SAMPLES (PRIMARILY GUT, BUT ALSO MOUTH, SKIN AND OTHER BODY SITES) FROM PARTICIPATING COMMUNITIES. THESE SAMPLES ARE THEN CHARACTERIZED AND, FROM THEM, THE GMBC GENERATES BACTERIAL ISOLATES. RESULTING RESEARCH MATERIALS AND ASSOCIATED DATA ARE SHARED THROUGH THE GMBC COLLECTIONTHE MOST GLOBALLY REPRESENTATIVE COLLECTION OF ITS KIND THAT PROVIDES SCIENTISTS ACCESS TO PREVIOUSLY UNAVAILABLE BIODIVERSITY. TO DATE, THE GMBC PROGRAM AT OPENBIOME HAS WORKED WITH OVER 80 RESEARCH COLLABORATORS TO COLLECT AND SHARE MICROBIOME DIVERSITY DERIVED FROM THE STOOL SAMPLES OF 1,200+ PARTICIPANTS FROM MORE THAN 30 PREVIOUSLY UNDERREPRESENTED COMMUNITIES.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Lisa Serwin Director/board Chair | OfficerTrustee | 10 | $0 |
James Bildner Director/treasurer | OfficerTrustee | 2 | $0 |
Jane Williams Director/secretary | OfficerTrustee | 2 | $0 |
Neil Rasmussen Director/vice Chair | OfficerTrustee | 2 | $0 |
Eric Alm PHD Director | Trustee | 2 | $0 |
Paul Leech Chief Operating Officer (as Of 9/22) | Officer | 40 | $59,792 |
Vendor Name (Service) | Service Year | Compensation |
---|---|---|
Mintz Legal | 12/30/22 | $102,851 |
Laura Folk Quality | 12/30/22 | $174,149 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $0 |
Related organizations | $0 |
Government grants | $1,155,317 |
All other contributions, gifts, grants, and similar amounts not included above | $57,467 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $1,212,784 |
Total Program Service Revenue | $1,026,171 |
Investment income | $23,357 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $1,325,000 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | $2,379,128 |
Net Income from Fundraising Events | $0 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $364,090 |
Miscellaneous Revenue | $0 |
Total Revenue | $6,330,530 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $0 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $0 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $498,529 |
Compensation of current officers, directors, key employees. | $72,758 |
Compensation to disqualified persons | $0 |
Other salaries and wages | $925,086 |
Pension plan accruals and contributions | $43,562 |
Other employee benefits | $333,108 |
Payroll taxes | $123,719 |
Fees for services: Management | $0 |
Fees for services: Legal | $76,627 |
Fees for services: Accounting | $59,700 |
Fees for services: Lobbying | $0 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $0 |
Fees for services: Other | $0 |
Advertising and promotion | $0 |
Office expenses | $173,493 |
Information technology | $196,112 |
Royalties | $3,075 |
Occupancy | $276,579 |
Travel | $18,036 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $34,256 |
Interest | $0 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $87,101 |
Insurance | $144,913 |
All other expenses | $0 |
Total functional expenses | $3,245,836 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $7,553,224 |
Savings and temporary cash investments | $0 |
Pledges and grants receivable | $0 |
Accounts receivable, net | $660,668 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $2,183,545 |
Prepaid expenses and deferred charges | $157,105 |
Net Land, buildings, and equipment | $62,545 |
Investments—publicly traded securities | $0 |
Investments—other securities | $0 |
Investments—program-related | $0 |
Intangible assets | $0 |
Other assets | $270,455 |
Total assets | $10,887,542 |
Accounts payable and accrued expenses | $353,266 |
Grants payable | $0 |
Deferred revenue | $0 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $1,090,595 |
Total liabilities | $1,443,861 |
Net assets without donor restrictions | $9,443,681 |
Net assets with donor restrictions | $0 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $10,887,542 |
Organization Name | Assets | Revenue |
---|---|---|
Microbiome Health Research Institute Woburn, MA | $10,887,542 | $6,330,530 |
National Pressure Ulcer Advisory Panel Inc Westford, MA | $1,607,683 | $1,228,538 |
Athletes Vs Crohns Inc Scarsdale, NY | $149,148 | $0 |
Digestive Disease Research Foundation New York, NY | $718,952 | $179,379 |
Bockus International Society Of Gastroenterology Inc East Hills, NY | $777,628 | $73,224 |